• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
NICO CorporationSecondary logo

NICO Corporation

Dedicated to revolutionizing minimally invasive neurosurgery

  • Home
  • Patients
  • Professionals
    • Our Capabilities
    • Our Integrated System
    • Our Surgical Focus
    • Our Impact
    • Published Data
    • Investigator Initiated Study Program
    • Donation Request
    • Global Distribution
    • Neurosurgeon Training
  • Company
    • Our Mission
    • Our Leadership Team
    • News & Events

Our Clinical & Economic Impact

Home » Our Clinical & Economic Impact

Evidence is Mounting

  • 40,000+ Patient Lives Impacted

  • 35+ Presentations at National and International Neurosurgical Conferences

  • 150+ Peer-reviewed Publications and Abstracts

These independent publications show:

  • Repeated Safety;
  • Efficiency; and
  • Reduced Surgical Morbidity

associated with a wide range of abnormalities when using NICO technologies as a standardized method for contributing to improved clinical outcomes.

NICO supports healthcare’s commitment to achieving the Triple Aim
Evidence also suggests MIPS supported by BrainPath provides economic value for the hospital when analyzing the entire episode of care. This, combined with a reduction in the ICU length of stay, improves the patient experience of care and supports healthcare’s commitment to achieving the Triple Aim.

 


 

ICH Evacuation Clinical Impact

Clinical Advantages

Using a standardized approach (trans-sulcal, parafascicular) to access bleeds and standardized technology (BrainPath for access and Myriad NOVUS to mechanically evacuate the clot) provides three clinical advantages:

  1. Intervention in an acute time period without clot stability1
  2. Effective hemostasis management using a bi-manual technique
  3. Consistent evacuation >90% of clot1,2,3,4

Selected Clinical Outcomes

  • 98.2% median clot evacuation1
  • mRS <3 in 63% of patients2
  • <15mL EOT volumes in 94 of 98 patients studied1,2,3,4
  • Statistically significant post-op GCS improvement1,3
  • Mortality Improvement (vs pre-op ICH score)1,3
  • Decrease in ICU length of stay from 12 to 45

clinical evidence-for-ICH-evaluation-NICO

Selected Economic Outcomes

  • Increased surgical options for patients vs medical management.
  • Reduction in repetitive non-contrast CT scans.3
  • Throughput
    • 55% decrease in mechanical ventilation days.3
    • 18% decrease in neuro-ICU LOS days, freeing-up neuro-ICU beds.3
    • 47% decrease in cost per patient.3

 


 

Tumor & Brain Biopsy Clinical Impact

In a 2020 Meta-Analysis published in World Neurosurgery that included 29 publications meeting rigorous inclusion criteria, more than 280 patients were included in a review of current studies on use of MIPS with BrainPath. The outcomes not only confirmed the success of non-disruptive, trans-sulcal access and the ability to achieve microsurgical techniques and hemostasis management, but also the following:

Selected Clinical Outcomes

  • Lower surgical morbidity / post-operative complications (8.3%) as compared to traditional craniotomy6
  • 80.6% of cases achieved gross total resection6
  • 100% gross total resection for colloid cyst6
  • 100% success in achieving pathologic diagnosis for all biopsy cases6

Selected Economic Outcomes

  • Several cohorts have reported shorter length of hospital stay with MIPS using BrainPath as compared to traditional craniotomy, with benefits of:
    • Minimal wound disruption6
    • Decreased risk of post-operative wound infection6
    • Lower post-operative complications6
Clinical Outcomes Tumor
economic outcomes of tumor and brain biopsy NICO

 


 

Economic Impact

Clinical paper shows substantial economic benefit to hospital.

  • Greater than 50% average reduction in ICU length of stay5
  • Average economic benefit to the hospital of $12,000 per patient for 28 patients5
  • Net estimated benefit to the bottom line of $329,6595
Economic Benefit of BrainPath Surgery

Presentations by Sid Norton

Click HERE to listen to the lead author discuss their analysis of MIPS with BrainPath in neurosurgery.

Watch video abstract presented by Sid Norton.

Sid Norton, Finance AVP for Pediatrics at Intermountain Healthcare, CFO Primary Children's HospitalSidney P Norton
Finance AVP for Pediatrics,
CFO Primary Children’s Hospital,
Intermountain Healthcare


 

Citations

  1. Bauer, et al.”Initial Single-center technical experience with the BrainPath system for acute Intracerebral hemorrhage evacuation” Operative Neurosurgery 2016
  2. Labib, et al, “The safety and feasibility of image-guided BrainPath mediated transsulcul hematoma evacuation: a Multicenter trial” Neurosurgery 4, April 2017: 515-524
  3. Sujijantarat, et al. “Trans-sulcal endoport assisted evacuation of supratentorial Intracerebral hemorrhage “Operative Neurosurgery 0:1-8,2017
  4. Rutkowski, M., Song, I., Mack, W. and Zada, G., 2020. Outcomes After Minimally Invasive Parafascicular Surgery For Intracerebral Hemorrhage: A Single-Center Experience
  5. Shah,et al. Technology that achieves the Triple Aim. ClinicoEconomics and Outcomes Research. 2017;9 519-523
  6. Mansour S. et al The use of BrainPath Tubular Retractors in the Management of Deep Brain Lesions: A Review of Current Studies. World Neurosurg. (2020) 134:155-163

Primary Sidebar

Patient Success Stories

Ed – Tumor

Ed Cerninka knew something was wrong. He sought medical help from a surgeon who had recently learned about NICO BrainPath. Ed's tumor was removed with no major issues.
Ed Cerninka Story Tumor

Watch Ed’s Story

https://youtu.be/ziZfF55uU5s

Bryan – Hemorrhagic Stroke

Bryan Melchor experienced a brain stem stoke. He benefited from NICO's BrainPath surgery and he met his hero who provided hope and encouragement.

Bryan Melchor Story Hemorrhagic Stroke

Read Bryan’s Story

Read Bryan’s Letter


Ryan – Tumor

Ryan Vincent had two brain tumors, 23 years apart. He describes both experiences and compares his first conventional tumor removal with the new BrainPath technique.
Ryan Vincent Story Tumor

Watch Ryan’s Story

https://www.youtube.com/watch?v=cowERgay_Z4

Cathy – Hemorrhagic Stroke

Cathy had a stroke. A neurosurgeon at the Cleveland Clinic performed a new kind of brain surgery using new technology called BrainPath.
Cathy Alexander Story Hemorrhagic Stroke

Read Cathy’s Story


Virginia – Hemorrhagic Stroke

Virginia was rushed to the NorthShore Neurological Institute where she underwent revolutionary brain surgery.
Virginia's Story Hemorrhagic Stroke

Read Virginia’s Story


Tom Corbin – Hemorraghic Stroke

Corbin was in the back of his house when he realized something was terribly wrong. He would later learn that an artery in his brain had burst, a condition called intracerebral hemorrhage, which is fatal in about half of all cases.
Tom's Story Hemorraghic Stroke

Read Tom’s Story


Footer

OUR MISSION is SIMPLE

We provide proven and patented technologies that integrate imaging and intervention for a safe, minimally disruptive approach to brain surgery. This integration drives efficiencies for the patient, surgeon and healthcare provider.

Customer Service

 Tel: (317) 660-7118
 Email Us

NICO has a 24-hour hotline for urgent clinical requests.
 1-888-632-7071 ext. 213

Stay Connected

  • LinkedIn
  • Twitter
  • YouTube

Search Our Website

privacy policy  ·   terms of use  ·   patents

Copyright © 2021 · Nico Corporation · NICO Myriad and BrainPath are “tools” not “treatments”. Physicians should use their best judgment and clinical experience when deciding how to use the Myriad and BrainPath. The latest information, including contraindications, warnings and precautions can be obtained by consulting product labeling or your local NICO representative.